SFCM
TSHA icon

Seven Fleet Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Seven Fleet Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.94M Buy
1,504,400
+878,692
+140% +$5.2M 1.64% 13
2026
Q1 		$2.8M Buy
625,708
+458,485
+274% +$2.13M 0.88% 29
2025
Q4 		$920K Buy
+167,223
New +$812K 0.62% 30

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Seven Fleet Capital Management's TSHA Position: Q2 2026 in Review

Seven Fleet Capital Management increased its Taysha Gene Therapies (TSHA) stake by 140% in Q2 2026, buying an estimated $5.2M and bringing the position to 1,504,400 shares worth $9.94M. The position accounts for 1.64% of the portfolio, ranked #13.

Seven Fleet Capital Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Seven Fleet Capital Management held 1,504,400 shares of Taysha Gene Therapies worth $9.94M as of Q2 2026.
  • Seven Fleet Capital Management bought 878,692 Taysha Gene Therapies shares in Q2 2026, an estimated $5.2M.
  • Taysha Gene Therapies made up 1.64% of Seven Fleet Capital Management's portfolio in Q2 2026, its #13 holding.
  • Seven Fleet Capital Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.